Abstract
Myriad RBM’s quantitative, multiplexed, immunoassay services have been successfully used in nearly 30 publications on diabetes and other metabolic disorders as part of a targeted proteomics approach to biomarker discovery and validation. Learn more about how our services meet the needs of researchers in this field.
Get Access to the Application Notes
Details
- 21 Jul 2015
- Application Notes, Metabolic
